Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Carisma Therapeutics ( (CARM) ).
On August 5, 2025, Carisma Therapeutics Inc. held a Special Meeting of Stockholders where they approved a reverse stock split of the company’s common stock, with the exact ratio to be determined by the Board of Directors. The meeting also addressed the potential adjournment to solicit more proxies, which was deemed unnecessary as there were sufficient votes to approve the reverse split proposal.
The most recent analyst rating on (CARM) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.
Spark’s Take on CARM Stock
According to Spark, TipRanks’ AI Analyst, CARM is a Neutral.
Carisma Therapeutics faces severe financial difficulties, with negative equity and ongoing losses. Technical indicators suggest a bearish outlook, while valuation metrics reflect the company’s struggling position. The recent corporate event highlights compliance issues but also shows attempts to address these challenges.
To see Spark’s full report on CARM stock, click here.
More about Carisma Therapeutics
Average Trading Volume: 14,364,547
Technical Sentiment Signal: Strong Sell
Current Market Cap: $12.75M
Find detailed analytics on CARM stock on TipRanks’ Stock Analysis page.